Sling Therapeutics, Inc.
A clinical-stage biotechnology company developing an oral drug candidate for thyroid eye disease.
$123MSeries C
LeadF
Forbion
Activity from announced rounds
Activity in this selectionmch-94eda40b
- Rounds participated in
- 7
- Confirmed lead rounds
- 1 5 roles undisclosed
- New companies
- 7 First participation on record · 0 follow-on
- Funding in participating rounds
- $968M 7 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
7 in this selectionSolstice Oncology
A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment.
$225MSeries A
ParticipantRQ Bio
Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients
$115MSeries A
Role not disclosedCellCentric
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
$220MSeries D
Role not disclosedSlate Medicines
Advancing next-generation therapeutics for migraine and other headache disorders
$130MSeries A
Role not disclosedAltesa BioSciences
Clinical-stage developer of oral antiviral medicines for people with chronic lung disease.
$75MSeries B
Role not disclosedCorsera Health
Develops preventive RNAi medicines for cardiovascular disease prediction and prevention
$80MSeries A
Role not disclosed